In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia

Eastern Mediterranean Health Journal

Volumn 11, Issue 1-2, 2005, Pages 36-44

  Balkhy, H H ^a   Memish, Z A ^a   Shibl, A ^b   Elbashier, A ^c   Osoba, A ^d  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c QATIF CENTRAL HOSPITAL   (Saudi Arabia)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; SAUDI ARABIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; NAPHTHYRIDINES; OFLOXACIN; PIPERAZINES; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; SAUDI ARABIA; STREPTOCOCCUS PNEUMONIAE;

EID: 33644587692     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Blondeau JM. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. Journal of antimicrobials and chemotherapy, 1999, 43 (suppl. B):1-11.
2. Biedenbach DJ, Jones RN, Pfaller MA. Activity of BMS 284756 against 2681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagnostic microbiology and infectious disease, 2001, 39(4):245-50.
3. Biedenbach DJ, Jones RN. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. Diagnostic microbiology and infectious disease, 2002, 43(4):323-6.
4. Rittenhouse S et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. Journal of antimicrobials and chemotherapy, 2000, 45(suppl. 1): 23-7.
5. Gould IM, Forbes KJ, Gordon GS. Quinolone resistant Haemophilus influenzae. Journal of antimicrobials and chemotherapy, 1994, 33(1):187-8.
6. Biedenbach DJ, Jones RN. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagnostic microbiology and infectious disease, 2000, 36(4):255-9.
7. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, Twelfth Informational Supplement, M100-S12, vol. 22, no. 1. Wayne, Pennsylvania, National Committee for Clinical Laboratory Standards, 2002.
8. Bartlett JG et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Disease Society of America. Clinical infectious diseases, 1998, 26(4):811-38.
9. Bartlett JG et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease Society of America. Clinical infectious diseases, 2000, 31(2):347-82
10. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clinical infectious diseases, 2000, 30(2):243-54.
11. Niederman MS et al. The cost of treating community acquired pneumonia. Clinical therapeutics, 1998, 20(4):820-37.
12. Marre R, Trautmann M. Ambulant erworbene Atemwegsinfektionen. Aktuelle Daten zur Wirksamkeit und Resistenzsituation verschiedener Antibiotikagruppen gegenuber den wichtigsten bakteriellen Spezies. [Community acquired respiratory tract infections. Current data on the efficacy of various classes of antibiotics and antibiotic resistance of the main prevalent bacteria species.] Medizinische Klinik, 1999, 94(11):609-13.
13. Heffelfinger JD et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Archives of internal medicine, 2000, 160(10):1399-408.
14. Hooper DC. Flouroquinolone resistance among gram-positive cocci. Lancet infectious diseases, 2002, 2(9):530-8.
15. Doern GV et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States of America and Canada, 1997). Antimicrobial agents and chemotherapy, 1999, 43(2):385-9.
16. Jacobs MR et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrobial agents and chemotherapy, 1999, 43(8):1901-8.
17. Thornsberry C et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. Journal of antimicrobial chemotherapy, 1999, 44(6):749-59.
18. Felmingham D, Gruenberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of antimicrobial chemotherapy, 2000, 45:191-203.
19. Memish ZA, Shibl AM, Ahmed QA. Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. International journal of antimicrobial agents, 2002, 20(suppl. 1):1-12.
20. Vila J et al. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrobial agents and chemotherapy, 1999, 43(1):161-2.
21. Jordens JZ, Slack MPE. Haemophilus influenzae: then and now. European journal of clinical microbiology and infectious diseases, 1995, 14(11):935-48.
22. Chen DK et al. Decreased susceptibility of Streptococcus pneumoniae to flouroquinolones in Canada. Canadian Bacterial Surveillance Network. New England journal of medicine, 1999, 341(4):233-9.
23. Low DE et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrobial agents and chemotherapy, 2002, 46(5):1295-301.
24. Davidson R et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England journal of medicine, 2002, 346(10):747-50.
25. Chowdhury MNH, Mahgoub ES. Ampicillin-resistant Haemophilus influenzae in Riyadh, Saudi Arabia. Saudi medical journal, 1982, 3:100-5.
26. Shibl AM, Gaillot O. Susceptibility of clinically significant Haemophilus influenzae strains to oral antimicrobial agents used in Saudi Arabia. Chemotherapy, 1994, 40(6):399-403.
27. Qadri SMH, Lee GC, Ellis ME. Blactamase production in recent clinical isolates of Haemophilus influenzae and their susceptibility to cefaclor and other antimicrobial agents. Saudi medical journal, 1993, 14:59-61.
28. Kambal AM, Abdul Khaliq MR, Chowdhury NH. Susceptibility of Haemophilus influenzae to selected antimicrobial agents. Annals of Saudi medicine, 1996, 16(5):582-6.
29. Memish ZA et al. Streptococcus pneumoniae in Saudi Arabia: Antibiotic resistance and serotypes among recent clinical isolates. International journal of antimicrobial agents, 2004, 23(1):32-8.
30. El-Mouzan MI et al. Pneumococcal infections in eastern Saudi Arabia: serotypes and antibiotic sensitivity patterns. Tropical and geographical medicine, 1988, 40(3):213-317.
31. Qadri SM, Kroschinsky R. Prevalence of pneumococci with increased resistance to penicillin in Saudi Arabia. Annals of tropical medicine and parasitology, 1991, 85(2):259-62.
32. Rotimi VO, Feteih J, Barbor PRH. Prevalence of penicillin-resistant Streptococcus pneumoniae in a Saudi Arabian hospital. European journal of clinical microbiology and infectious diseases, 1995, 14(2):149-51.
33. Shibl AM et al. Penicilin-resistant and intermediate Streptococcus pneumoniae in Saudi Arabia. Journal of chemotherapy, 2000, 12(2):134-7.
34. El-Tahawy AT. Antimicrobial resistance of Streptococcus pneumoniae at a University Hospital in Saudi Arabia. Journal of chemotherapy, 2001, 13(2):148-53.
35. Al-Aqeeli AA, Guy ML, Al-Jumaah SA. Streptoccous pneumoniae resistance to penicillin and ceftriaxone in a tertiary care centre in Saudi Arabia. Saudi medical journal, 2002, 23(4):400-4.
36. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clinical infectious diseases, 2002, 34:1613-20.
37. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy, 1999, 43:187-9.
38. Memish ZA. Meningococcal disease and travel. Clinical infectious diseases, 2002, 34:84-90.
39. Babay HA. Isolation of Moraxella catarrhalis in patients at King Khalid University Hospital, Riyadh. Saudi medical journal, 2000, 21(9):860-3.
40. Zhanel GG et al. Animicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: Results of the Candadian Respiratory Organisms Susceptibility Study, 1997 to 2002. Antimicrobial agents and chemotherapy, 2003. 47(6): 1875-81.